Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine

Table 2 Demographic data of control, EMCI, and LMCI subjects

Variables	Control	EMCI	LMCI	P	Adjusted P value for pairwise comparisons
Male, n (%)	153 (41.7)	132 (42.3)	101 (41.4)	0.051²
Age, y	65 ± 8	65 ± 8	65 ± 7	0.153¹
Education year, y	12 ± 3	9 ± 3	9 ± 3	0.006¹	LMCI < Control P = 0.005
Smoker, n (%)	84 (22.9)	87 (27.9)	63 (25.8)	0.323²
Drinker, n (%)	88 (24.0)	69 (22.1)	54 (22.1)	0.806²
Hypertension, n (%)	131 (35.7)	126 (40.4)	102 (41.8)	0.254²
Diabetes, n (%)	66 (18.0)	76 (24.4)	42 (17.2)	0.054²
Hyperlipemia, n (%)	113 (30.8)	103 (33.0)	90 (36.9)	0.292²
CHD, n (%)	35 (9.5)	43 (13.8)	36 (14.8)	0.101²

¹P value for Kruskal-Wallis rank sum test for continuous variables with skewed distribution, which were presented as medians ± interquartile range. Adjusted P value by Bonferroni correction
²P value for Chi-square tests for categorical variables, which were presented as n (%)
Abbreviations: EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; CHD, coronary heart disease

ISSN: 1758-9193